Industry Summits
Pharma CEOs see risk-averse climate in U.S.
NEW YORK (Reuters) - Pharmaceutical companies see U.S. regulators applying a tougher standard to some new medicines by looking for evidence they are better than drugs already on the market, officials told Reuters this week. Full Article
Democrats to benefit some in U.S. health sector
NEW YORK (Reuters) - While Republicans vying for the U.S. presidency warn about Democratic plans for a "government takeover of healthcare," many companies in the sector see opportunities should a Democrat win. Full Article
Momentum builds for biogenerics, execs say
NEW YORK (Reuters) - Despite the failure by U.S. legislators to create a path this year for generic versions of biotech drugs, companies that have invested in the products say such legislation could pass in 2008 and yield generic biologics early in the next decade. Full Article
Stay connected. Get e-mailed alerts with schedules, speaker lists, and headlines from upcoming and live Industry Summits.
CVS, Medco paths diverge on retailing
NEW YORK (Reuters) - Shares of CVS Caremark Corp have soared 35 percent this year, but you might excuse investors for wishing their money had been elsewhere in 2007. Full Article
Novo sees advantages vs Byetta LAR
NEW YORK (Reuters) - Novo Nordisk A/S said on Thursday it believes its experimental type 2 diabetes treatment will be as effective as the Eli Lilly and Co drug expected to be its main rival and may have advantages that will win over patients. Full Article
Millennium keeps cool head amid acquisition heat
BOSTON (Reuters) - Biotechnology company Millennium Pharmaceuticals Inc said on Thursday that it won't be as aggressive as some of its rivals when it comes to bidding for experimental new drugs. Full Article | Video
Baxter capable of $1 bln in deals/yr
NEW YORK (Reuters) - Baxter International Inc has the capacity to make acquisitions worth $1 billion every year using its own cash flow, its chief executive told the Reuters Health Summit in New York. Full Article
Novo sees dimmed prospects for inhaled insulin
NEW YORK (Reuters) - Novo Nordisk A/S sees a limited market for inhaled insulin, but the company is forging ahead with its experimental product to ensure it can offer a complete package of diabetes medicines, a top executive said on Thursday. Full Article | Video
Teva sees U.S. generic share above 30 percent
NEW YORK (Reuters) - Teva Pharmaceutical Industries Ltd could see its U.S. generic-drug market share swell to more than 30 percent in the next five years, its North American chief said on Thursday. Full Article | Video
Personalized medicine slowly taking shape
NEW YORK (Reuters) - Personalized medicine -- tailoring treatments to an individual's genetic profile -- has been one of the main dreams of the gene revolution, but putting it into practice is proving tough. Full Article
More Health News
What are Summits?
Reuters Summits are your direct link to top business leaders, investors and regulators. Our journalists interview heavyweights in a particular industry, spin out hard-hitting breaking news and sharp analysis that can often move markets. If you want to understand what the insiders are thinking, look for Reuters Summits. Launch Full Video
Speakers
Upcoming Summits
| Global Wealth Management | Oct 13 - 15 | Boston, Geneva, Singapore |
| Central European Investment | Oct 20 - 22 | Vienna, Warsaw |
| Middle East Investment | Nov 3 - 5 | Dubai |
| China Summit | Nov 5 - 7 | Beijing |
| Global Finance | Nov 10 - 13 | New York, London, Hong Kong |
| Health | Nov 17 - 20 | New York |
| India Investment | Nov 24 - 26 | Mumbai and Bangalore |
| Media | Dec 1 - 4 | New York |
| Investment Outlook | Dec 8 - 11 | New York |
| Aerospace and Defense | Dec 15 - 17 | Washington, DC |
